Sugi Predict

Sugi Predict / Compounds / SCHEMBL389415

SCHEMBL389415

SCHEMBL389415

CC(C)(C)OC(=O)NC1(C(=O)NC(CCCO)c2ccc(Cl)cc2)CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ KIT P10721 2/20 0.42
▸ AKT1 P31749 3/20 0.42
▸ ROCK2 O75116 1/20 0.42
▸ AKT2 P31751 1/20 0.42
▸ KCNH2 Q12809 1/20 0.42
▸ AKT3 Q9Y243 1/20 0.42
▸ CNR1 P21554 1/20 0.40
▸ ATM Q13315 1/20 0.40
▸ MEN1 O00255 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ HTT P42858 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ NPSR1 Q6W5P4 1/20 0.39
▸ STS P08842 2/20 0.39
▸ DRD2 P14416 2/20 0.38
▸ ALOX15 P16050 1/20 0.38
▸ TSHR P16473 1/20 0.38
▸ RPS6KB1 P23443 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL391466 0.95 KIT (0.46) KITAKT1ROCK2AKT2AKT3
SCHEMBL391467 0.95 KIT (0.46) KITAKT1ROCK2AKT2AKT3
SCHEMBL20544519 0.93 AKT1 (0.42) KITAKT1ROCK2AKT2KCNH2
SCHEMBL20544738 0.87 RPS6KB1 (0.42) KITAKT1ROCK2AKT2AKT3
SCHEMBL392110 0.82 AKT1 (0.39) KITAKT1ROCK2AKT2KCNH2
SCHEMBL3808954 0.81 DRD2 (0.45) CNR1ATMMEN1KMT2AHTT
SCHEMBL3804529 0.80 DRD2 (0.43) CNR1ATMMEN1KMT2AHTT
SCHEMBL390940 0.80 AKT1 (0.72) AKT1ROCK2AKT2KCNH2AKT3
SCHEMBL391263 0.78 P2RY2 (0.47) —
SCHEMBL1001879 0.78 SMN1; SMN2 (0.57) MEN1KMT2AHTTSMN1; SMN2NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12252495-B2 Protein kinase B inhibitors ASTRAZENECA AB (SE) 2025-03-18 — — US disclosed
US-20240109902-A1 PROTEIN KINASE B INHIBITORS ASTRAZENECA AB (SE) 2024-04-04 — — US disclosed
US-11760760-B2 Protein kinase B inhibitors ASTRAZENECA AB (SE) 2023-09-19 — — US disclosed
US-11760760-B2 Protein kinase B inhibitors ASTRAZENECA AB (SE) 2023-09-19 — — US disclosed
US-11760760-B2 Protein kinase B inhibitors ASTRAZENECA AB (SE) 2023-09-19 — — US disclosed
US-20220220116-A1 PROTEIN KINASE B INHIBITORS ASTRAZENECA AB (SE) 2022-07-14 — — US disclosed
US-20220220116-A1 PROTEIN KINASE B INHIBITORS ASTRAZENECA AB (SE) 2022-07-14 — — US disclosed
US-11236095-B2 Protein kinase B inhibitors ASTRAZENECA AB (SE) 2022-02-01 — — US disclosed
US-11236095-B2 Protein kinase B inhibitors ASTRAZENECA AB (SE) 2022-02-01 — — US disclosed
US-20200239483-A1 PROTEIN KINASE B INHIBITORS ASTRAZENECA AB (SE) 2020-07-30 — — US disclosed
US-20120190679-A1 Novel Protein Kinase B Inhibitors - 060 ASTRAZENECA AB (SE) 2012-07-26 — — US disclosed
US-20120190679-A1 Novel Protein Kinase B Inhibitors - 060 ASTRAZENECA AB (SE) 2012-07-26 — — US disclosed
US-20120190679-A1 Novel Protein Kinase B Inhibitors - 060 ASTRAZENECA AB (SE) 2012-07-26 — — US disclosed
US-8101623-B2 Substituted pyrrolo[2,3-d]pyrimidine as a protein kinase B inhibitor ASTRAZENECA AB (SE) 2012-01-24 — — US disclosed
US-8101623-B2 Substituted pyrrolo[2,3-d]pyrimidine as a protein kinase B inhibitor ASTRAZENECA AB (SE) 2012-01-24 — — US disclosed
US-8101623-B2 Substituted pyrrolo[2,3-d]pyrimidine as a protein kinase B inhibitor ASTRAZENECA AB (SE) 2012-01-24 — — US disclosed
US-20090163524-A1 Novel Protein Kinase B Inhibitors - 060 ASTRAZENECA AB (SE) 2009-06-25 — — US disclosed
US-20090163524-A1 Novel Protein Kinase B Inhibitors - 060 ASTRAZENECA AB (SE) 2009-06-25 — — US disclosed
US-20090163524-A1 Novel Protein Kinase B Inhibitors - 060 ASTRAZENECA AB (SE) 2009-06-25 — — US disclosed
WO-2009047563-A1 PYRROLO [2, 3 -D] PYRIMIDIN DERIVATIVES AS PROTEIN KINASE B INHIBITORS ASTRAZENECA AB (SE) 2009-04-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12252495-B2 Protein kinase B inhibitors PRKAR2B, PRKCB, AKT1 KIT 522/4885AKT1 3/4885ROCK2 60/4885
US-20220220116-A1 PROTEIN KINASE B INHIBITORS PRKAR2B, PRKCB, AKT1 KIT 522/4885AKT1 3/4885ROCK2 60/4885
US-20240109902-A1 PROTEIN KINASE B INHIBITORS PRKAR2B, PRKCB, AKT1 KIT 522/4885AKT1 3/4885ROCK2 60/4885
US-20090163524-A1 Novel Protein Kinase B Inhibitors - 060 PRKAR2B, PRKCB, MAP3K20 KIT 536/4885AKT1 4/4885ROCK2 85/4885
US-20200239483-A1 PROTEIN KINASE B INHIBITORS PRKAR2B, PRKCB, AKT1 KIT 522/4885AKT1 3/4885ROCK2 60/4885
US-20120190679-A1 Novel Protein Kinase B Inhibitors - 060 PRKAR2B, PRKCB, MAP3K20 KIT 536/4885AKT1 4/4885ROCK2 85/4885
US-11236095-B2 Protein kinase B inhibitors PRKAR2B, PRKCB, AKT1 KIT 522/4885AKT1 3/4885ROCK2 60/4885
US-11760760-B2 Protein kinase B inhibitors PRKAR2B, PRKCB, AKT1 KIT 522/4885AKT1 3/4885ROCK2 60/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.